comprehensive -WSS

comprehensive

author：focus 2025-09-27 12:55:04 - browse：94

Sarepta - Cambridge -AP — Kristoffer Tripplaar/Sipa via AP

The Food and Drug Administration granted conditional approval Thursday to the first gene therapy for Duchenne muscular dystrophy. Regulators restricted the treatment to younger patients, with additional data required to broaden its use.

The gene therapy, called Elevydis, is made by Sarepta Therapeutics. The company will charge $3.2 million for the treatment, making it the U.S.’s second most expensive drug, behind a recently approved gene therapy for hemophilia. CEO Doug Ingram said on a conference call the price was below what a recently published company-funded analysis found would be cost-effective.

“The approval of Elevidys is a watershed moment for the treatment of Duchenne. Elevydis is the first and only gene therapy approved for Duchenne, and this approval brings us closer to our goal of bringing forward a treatment that provides the potential to alter the trajectory of this degenerative disease,” Ingram said.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Affirmative action in medical school literally saved lives
Next article： Amylyx and the next ALS drug test, plus a chat with CRISPR's CEO

knowledge

WSS

CMS got Medicare Advantage quality rating wrong, judge rules

Congress must protect the remaining independent doctors

A new initiative will help leaders fight the next pandemic

Lilly to acquire Dermira for $1.1 billion, adding eczema drug to its pipeline

Abbott's new heart device gets FDA advisory panel nod

FTC loses bid to block Novant's North Carolina hospital merger

leisure time

comprehensive

focus

How one medical school became remarkably diverse

ASCO Takeaways: Winners, snoozers, and the art of cancer care

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

ASCO Takeaways: Winners, snoozers, and the art of cancer care

As demand for Covid shots wanes, Moderna seeks its next success

How CO2 helps viruses stay alive longer in the air

Anesthesiologist group: stop taking Ozempic before surgery

Juul documents reveal insider tactics on political lobbying

Moonlake's readout produced a cash windfall. Risks remain

Tome Biosciences co

entertainment

Websites selling Wegovy, Zepbound ingredients targeted by FDA

Eli Lilly’s Zepbound improved liver scarring in mid

Study gives hint on South Asians’ higher risk of cardiovascular disease

Bernie Sanders gets little from pharma CEOs on drug prices

CMS got Medicare Advantage quality rating wrong, judge rules

ACIP vaccine advisory panel sees its vacancies filled

focus

entertainment

knowledge

explore